Liver Fibrosis Staging with Gadolinium Ethoxybenzyl Diethylenetriamine Penta-Acetic Acid-Enhanced: A Systematic Review and Meta-Analysis

(E-pub Ahead of Print)

Author(s): Lu-Yao Lai, Meng-Ping Huang, Song Su, Jian Shu*

Journal Name: Current Medical Imaging
Formerly: Current Medical Imaging Reviews


Become EABM
Become Reviewer
Call for Editor

Abstract:

Objective: While liver biopsy is the golden standard for liver-fibrosis diagnosis, it’s also invasive and has many limitations. Non-invasive techniques such as magnetic resonance imaging (MRI) need to be further developed for liver fibrosis staging. This study aimed to evaluate the diagnostic accuracy of gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid (Gd-EOB-DTPA)-enhanced MRI for liver fibrosis through systematic review and meta-analysis.

Methods: This study comprehensively searched relevant article in PubMed, Embase, and the Cochrane Library published from 2004 to 2018 to find studies analyzing the diagnostic accuracy of Gd-EOB-DTPA-enhanced MRI for liver fibrosis. Two reviewers independently screened the retrieved articles, extracted the required data from the included studies, and evaluated the methodological quality of the studies. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristics (SROC) curve were assessed.

Results: This study finally included 16 studies (n = 1,599) and selected a random-effects model based on the results of the I 2 statistic to combine them. The areas under the SROC curve for the detection of F1 or greater, F2 or greater, F3 or greater, or F4 liver fibrosis were 0.8669, 0.8399, 0.8481, and 0.8858, respectively.

Conclusion: Gd-EOB-DTPA-enhanced MRI showed a good diagnostic performance for staging liver fibrosis, especially for F4 liver fibrosis.

Keywords: Radiology, magnetic resonance imaging, liver diseases, liver cirrhosis, contrast Media, gadolinium ethoxybenzyl DTPA. Radiology, magnetic resonance imaging, liver diseases, liver cirrhosis, contrast Media, gadolinium ethoxybenzyl DTPA.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573405616666201130101229
Price: $95

Article Metrics

PDF: 7